DK0799311T3 - Human kemokin beta-9 - Google Patents
Human kemokin beta-9Info
- Publication number
- DK0799311T3 DK0799311T3 DK95923661T DK95923661T DK0799311T3 DK 0799311 T3 DK0799311 T3 DK 0799311T3 DK 95923661 T DK95923661 T DK 95923661T DK 95923661 T DK95923661 T DK 95923661T DK 0799311 T3 DK0799311 T3 DK 0799311T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptides
- ckbeta
- disclosed
- autoimmune
- human chemokine
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title abstract 2
- 108010012236 Chemokines Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 abstract 1
- 206010065553 Bone marrow failure Diseases 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000001524 infective effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29425194A | 1994-08-23 | 1994-08-23 | |
| PCT/US1995/006260 WO1996006169A1 (fr) | 1994-08-23 | 1995-06-06 | Chemokine beta 9 humaine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0799311T3 true DK0799311T3 (da) | 2005-07-11 |
Family
ID=23132551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95923661T DK0799311T3 (da) | 1994-08-23 | 1995-06-06 | Human kemokin beta-9 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US6518046B1 (fr) |
| EP (1) | EP0799311B1 (fr) |
| JP (2) | JPH10505493A (fr) |
| KR (1) | KR970705635A (fr) |
| AT (1) | ATE290080T1 (fr) |
| AU (1) | AU708558B2 (fr) |
| CA (1) | CA2198206A1 (fr) |
| DE (1) | DE69534044T2 (fr) |
| DK (1) | DK0799311T3 (fr) |
| ES (1) | ES2235172T3 (fr) |
| MX (1) | MX9701330A (fr) |
| NZ (1) | NZ288799A (fr) |
| PT (1) | PT799311E (fr) |
| WO (1) | WO1996006169A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391589B1 (en) | 1994-08-23 | 2002-05-21 | Human Genome Sciences, Inc. | Human chemokine beta-10 mutant polypeptides |
| US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
| US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
| US7005509B1 (en) * | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
| US6290948B1 (en) | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
| CA2267092A1 (fr) * | 1996-10-02 | 1998-04-09 | Schering Corporation | Chemokines mammaliennes |
| AU5496798A (en) * | 1997-01-20 | 1998-08-07 | Shionogi & Co., Ltd. | Human cc chemokine slc |
| CA2295982A1 (fr) * | 1997-06-11 | 1998-12-17 | Genetics Institute, Inc. | Proteines humaines l105 et polynucleotides codant lesdites proteines |
| US6084071A (en) * | 1997-06-11 | 2000-07-04 | Genetics Institute | Human L105 polypeptides and polynucleotides encoding same |
| US6153441A (en) * | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
| AU2715700A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| EP2261256A3 (fr) | 1999-11-24 | 2011-03-02 | Schering Corporation | Procedes d'inhibition de metastases |
| WO2002085286A2 (fr) * | 2001-04-18 | 2002-10-31 | The Regents Of The University Of California | Procedes permettant d'utiliser la chimiokine d'organes lymphoides secondaires pour moduler des processus physiologiques chez des mammiferes |
| US20020168358A1 (en) * | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
| WO2003092597A2 (fr) | 2002-05-01 | 2003-11-13 | Human Genome Sciences, Inc. | Anticorps a liaison specifique avec la chimiokine beta-4 (ck-b4) |
| US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
| WO2007136707A2 (fr) * | 2006-05-17 | 2007-11-29 | University Of Utah Research Foundation | Méthodes et compositions pour la régulation des éosinophiles |
| PE20180249A1 (es) | 2010-11-19 | 2018-02-02 | Eisai Randd Man Co Ltd | Anticuerpos neutralizadores anti-ccl20 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005198A1 (fr) | 1990-09-14 | 1992-04-02 | Chiron Corporation | Expression de proteines inductibles par macrophages (mip) dans des cellules de levure |
| US7005509B1 (en) | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
-
1995
- 1995-06-06 AT AT95923661T patent/ATE290080T1/de active
- 1995-06-06 WO PCT/US1995/006260 patent/WO1996006169A1/fr active IP Right Grant
- 1995-06-06 MX MX9701330A patent/MX9701330A/es unknown
- 1995-06-06 DE DE69534044T patent/DE69534044T2/de not_active Expired - Lifetime
- 1995-06-06 PT PT95923661T patent/PT799311E/pt unknown
- 1995-06-06 ES ES95923661T patent/ES2235172T3/es not_active Expired - Lifetime
- 1995-06-06 NZ NZ288799A patent/NZ288799A/xx not_active IP Right Cessation
- 1995-06-06 KR KR1019970701144A patent/KR970705635A/ko not_active Application Discontinuation
- 1995-06-06 DK DK95923661T patent/DK0799311T3/da active
- 1995-06-06 AU AU28141/95A patent/AU708558B2/en not_active Ceased
- 1995-06-06 CA CA002198206A patent/CA2198206A1/fr not_active Abandoned
- 1995-06-06 JP JP8508037A patent/JPH10505493A/ja not_active Ceased
- 1995-06-06 US US08/793,381 patent/US6518046B1/en not_active Expired - Lifetime
- 1995-06-06 EP EP95923661A patent/EP0799311B1/fr not_active Expired - Lifetime
-
2002
- 2002-06-03 JP JP2002161804A patent/JP2003047492A/ja active Pending
- 2002-12-27 US US10/329,472 patent/US7097985B2/en not_active Expired - Fee Related
-
2005
- 2005-10-28 US US11/260,166 patent/US7198944B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2198206A1 (fr) | 1996-02-29 |
| DE69534044D1 (de) | 2005-04-07 |
| US7097985B2 (en) | 2006-08-29 |
| MX9701330A (es) | 1998-02-28 |
| US20060040313A1 (en) | 2006-02-23 |
| ATE290080T1 (de) | 2005-03-15 |
| AU708558B2 (en) | 1999-08-05 |
| EP0799311A1 (fr) | 1997-10-08 |
| AU2814195A (en) | 1996-03-14 |
| NZ288799A (en) | 1999-06-29 |
| ES2235172T3 (es) | 2005-07-01 |
| PT799311E (pt) | 2005-05-31 |
| KR970705635A (ko) | 1997-10-09 |
| US20050244888A1 (en) | 2005-11-03 |
| WO1996006169A1 (fr) | 1996-02-29 |
| DE69534044T2 (de) | 2005-12-29 |
| EP0799311B1 (fr) | 2005-03-02 |
| JP2003047492A (ja) | 2003-02-18 |
| US6518046B1 (en) | 2003-02-11 |
| US7198944B2 (en) | 2007-04-03 |
| EP0799311A4 (fr) | 1998-09-30 |
| JPH10505493A (ja) | 1998-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE262345T1 (de) | Menschliche chemokin-polypeptide | |
| DE69534044D1 (de) | Menschliches beta-9 chemokin | |
| MX9708537A (es) | Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas. | |
| DE69533627D1 (en) | Humanes chemokin beta-13 | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| BG64881B2 (en) | TNF-BINDING PROTEINS | |
| NZ332318A (en) | Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses | |
| ATE365796T1 (de) | Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta | |
| EP1015488A4 (fr) | Proteine de type recepteur d'interleukine 17 | |
| ES2068791T1 (es) | Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido. | |
| ATE165980T1 (de) | Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren | |
| DE69433747D1 (de) | Calcitoninrezeptor | |
| WO2003080856A3 (fr) | Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees | |
| WO2003029423A3 (fr) | Polypeptides therapeutiques, acides nucleiques codant ceux-ci et procedes d'utilisation | |
| ATE472599T1 (de) | Chemokin alpha-5 | |
| WO2003031571A3 (fr) | Nouvelles proteines humaines, polynucleotides les codant et methodes d'utilisation afferentes | |
| WO2003022998A3 (fr) | Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation correspondantes | |
| WO2003085124A8 (fr) | Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees | |
| MX9709090A (es) | Quimiocina beta-11 humana y quimiocina alfa-1 humana. | |
| WO2003064589A3 (fr) | Polypeptides therapeutiques, acides nucleiques les codant et leurs methodes d'utilisation | |
| WO2003050245A3 (fr) | Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation | |
| WO2003004617A8 (fr) | Nouvelles proteines humaines, polynucleotides codant pour ces proteines et procedes d'utilisation associes | |
| WO2004022723A3 (fr) | Polypeptides therapeutiques, acides nucleiques les codant, et procedes d'utilisation | |
| WO2004015079A3 (fr) | Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et leurs procedes d'utilisation | |
| WO2003040327A3 (fr) | Nouvelles proteines humaines, polynucleotides codant ces dernieres et leurs methodes d'utilisation |